Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device .Credit: Aptar Group.

The US Food and Drug Administration (FDA) has approved Aptar Group’s Unidose Liquid System to treat acute repetitive seizures in those with epilepsy.

Claimed to be the first and only nasal rescue treatment for seizures, Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device that can deliver a formulation in an emergency.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Non-healthcare professionals can administer the nasal delivery device to a patient during or after a seizure.

When the patient or caregiver presses the small plunger on the bottom of the device, the drug is released in a single spray into the nostril, where the nasal mucosa quickly absorbs it.

Recently, Aptar acquired Noble International, which developed a trainer device for use as part of a patient onboarding programme for the new device.

Aptar president and CEO Stephan Tanda said: “This approval and successful market launch further demonstrate the broad potential for Aptar’s patient-friendly drug delivery solutions and service offerings which help our pharmaceutical customers address unmet healthcare needs.

“We are pleased to offer a broad portfolio of innovative technologies and a wide array of services to meet the highest quality standards of the pharmaceutical industry.”

Aptar Pharma president Gael Touya said: “The launch of our Unidose System on the first and only USFDA approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharma’s ability to help our customers develop and launch complex treatments.

“When we combine our nasal systems’ capabilities with Noble’s training devices for onboarding, we bring added value to our customers and further convenience for patients and consumers worldwide.”